AMCP Statement on PCMA Litigation to Halt Trump Rebate Rule
Alexandria, Va., Jan. 11, 2021 — AMCP released the below statement regarding PCMA’s lawsuit to halt the Trump administration’s rebate rule from going into effect.
Statement from Susan Cantrell, AMCP chief executive officer:
"In the final days of its tenure, the Trump administration is making a last ditch effort to implement a rule that would significantly increase premiums for 90% of Medicare Part D recipients. The rule would increase costs for one of our country’s most vulnerable populations — seniors — potentially destabilizing the Part D program, while also costing taxpayers hundreds of billions of dollars over the next decade. Additionally, the Trump administration circumvented the regular rulemaking process established by the Administrative Procedure Act and ignored thousands of comments from stakeholders opposed to this action.
“AMCP is firmly opposed to this rebate rule. We stand behind the lawsuit filed by PCMA to halt the rule and protect Medicare Part D. We will continue to work with our partners and lawmakers to ensure patients have access to the medications they need at costs they can afford.”
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.